Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
Open Access
- 1 January 2020
- journal article
- editorial
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Balancing benefits and risks in the era of biologicsTherapeutic Advances in Musculoskeletal Disease, 2019
- The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosisTherapeutic Advances in Musculoskeletal Disease, 2018
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trialThe Lancet, 2017
- Romosozumab or Alendronate for Fracture Prevention in Women with OsteoporosisThe New England Journal of Medicine, 2017
- Romosozumab Treatment in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2016
- Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseasesTherapeutic Advances in Musculoskeletal Disease, 2013